Skip to main content
. 2022 Jul 14;17(7):e0271327. doi: 10.1371/journal.pone.0271327

Fig 3. Pain in response to topical lidocaine.

Fig 3

(A) Evaluation of acute (spontaneous) pain (NRS, 0–10) of 27 patients at the time of visit (t = 0) and upon a lidocaine 5% patch applied to the assessed neuropathic skin site at 0.5–12 hours after application. (B) Acute (spontaneous) pain (NRS, 0–10) at the time of investigation (t 0) and in response to a lidocaine 5% patch at 0.5–12 hours after application in patients that reported a pain reduction exceeding NRS 1 compared to t 0 (“pain amelioration”, solid squares), pain enhancement of t 0 exceeding NRS 1 (“pain elevation”, open diamonds), and patients without lidocaine effect on t 0 (NRS changes– 1 to 1, open circles). Hash symbol indicates significant differences between the patients’ group (p < 0.0001, ANOVA) and asterisks indicate significance compared to t 0 acute (spontaneous) pain (p < 0.05, Fisher’s Least Significant).